Regeneron’s Antibody Drug Lower Threat of Covid-19 by 82%, Firm Says

Regeneron Prescription drugs Inc. mentioned its monoclonal antibody drug continued to offer robust safety towards Covid-19 an infection for eight months, lowering the danger of contracting the illness by 81.6% in contrast with a placebo in a long-term examine.

Regeneron mentioned on Monday that the info present the drug, referred to as REGEN-COV, can present long-lasting short-term immunity towards Covid-19, which may make it a sexy possibility for individuals who don’t reply to vaccines as a result of they’ve impaired immune techniques.